This document has been approved by Saudi Food and Drug Authority (SFDA).

VECANZOL® (voriconazole)

PATIENT ALERT CARD

Please carry this card with you all times

Your name:	
Date VECANZOL first prescribed:	
Treating doctor's name:	
Treatment hospital name	
Treatment hospital phone number:	

1.0- Sep 2024

www.mspharma.com

MSpharma

This card contains important safety information you need to be aware of before you are given VECANZOL® for prevention of fungal infections or during treatment with VECANZOL® for your fungal infection.

If you do not understand this information, please ask your doctor to explain it to you.

Show this card to any doctor or healthcare professional involved in your care. See the VECANZOL® package leaflet for more information.

You should avoid exposure to direct sunlight during VECANZOL® treatment.

It is important to cover sun exposed areas of skin and use sufficient sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun's UV rays can occur. There is a small chance that skin cancer could develop over time. Please ensure you undergo all follow-up visits for blood tests or skin evaluations arranged by your doctor.

Please have a list of all your other medicines and medical conditions available at each visit to a healthcare professional.

You should contact your doctor immediately if you experience:

Sunburn or severe skin reaction following exposure to light or sun.

Reporting of Side effects:

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

To Report any Adverse Drug Reaction or Concerns Please call:

Pharmacovigilance Department at MS Pharma:

Email: pharmacovigilance@mspharma.com

Website: www.mspharma.com

Phone No: + 966112790122 Ext. 6013

•The National Pharmacovigilance Center (NPC): (Saudi food and drug authority)

Email: npc.drug@sfda.gov.sa

Call Center: 19999

Website: https://ade.sfda.gov.sa/

QR Code:

